New and updated preclinical data presented at the American Society of Hematology Annual Meeting in New Orleans, by: Ajax Therapeutics, Biomea Fusion, Cimeio Therapeutics, Fate Therapeutics, Graphite Bio, GT Biopharma, Ichnos Sciences, IGM Biosciences, Incyte, Kronos Bio, Kymera Therapeutics, Monopar Therapeutics, Orum Therapeutics, OSE Immunotherapeutics, Poseida Therapeutics, Puretech Health, Schrödinger, Senti Biosciences, Vincerx Pharma, Wugen.
Preliminary preclinical data have been reported for Enliven Therapeutics Inc.’s ATP-competitive small-molecule ABL1 tyrosine kinase inhibitor (TKI) ELVN-001. In vitro antiproliferative effects, assessed using the biomarker Tyr207-phosphorylated CRKL, demonstrated that ELVN-001 had potent activity with IC50 values ranging from 19 to 112 nM against BCR-ABL1-driven chronic myeloid leukemia (CML) cell lines in the presence of 50% to 100% human serum.
Janssen Pharmaceutica NV reported on the company’s novel fully human immunoglobulin G1 CD79bxCD20xCD3 trispecific antibody JNJ-80948543, comprising an anti-CD3 ε single-chain variable fragment (scFv), an anti-CD20 scFv, and an anti-CD79b fragment antigen-binding (Fab) domain and an effector-silent Fc, designed to redirect T cells to treat patients whose disease no longer responds to previous lines of therapy.
Ichnos Sciences Inc. has presented data on the first-in-class trispecific BCMA and CD38 T-cell engager ISB-2001, which is based on the company’s TREAT (Trispecific Engagement by Antibodies based on the TCR) technology. The compound targets CD3 on T cells and cotargets BCMA and CD38 on multiple myeloma (MM) cells.
